|
🐜
|
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor
25 auth.
P. May,
R. Dean,
S. Lowe,
F. Martényi,
S. Sheehan,
L. Boggs,
S. Monk,
B. M. Mathes,
Dustin J Mergott,
B. Watson,
S. Stout,
D. Timm,
Elizabeth Smith Labell,
C. Gonzales,
M. Nakano,
...
S. Jhee,
M. Yen,
L. Ereshefsky,
T. Lindstrom,
D. Calligaro,
Patrick J. Cocke,
D. Greg Hall,
S. Friedrich,
Martin Citron,
J. Audia
|
8 |
2011 |
8
🐜
|
|
🐜
|
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans
31 auth.
P. May,
B. Willis,
S. Lowe,
R. Dean,
S. Monk,
Patrick J. Cocke,
J. Audia,
L. Boggs,
Anthony R. Borders,
R. Brier,
D. Calligaro,
Theresa A. Day,
L. Ereshefsky,
J. Erickson,
Hykop Gevorkyan,
...
C. Gonzales,
D. James,
S. Jhee,
S. Komjathy,
Linglin Li,
T. Lindstrom,
B. M. Mathes,
F. Martényi,
S. Sheehan,
S. Stout,
D. Timm,
G. Vaught,
B. Watson,
L. L. Winneroski,
Zhixiang Yang,
Dustin J Mergott
|
7 |
2015 |
7
🐜
|
|
🐜
|
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
19 auth.
B. Konicek,
A. Capen,
K. Credille,
P. Ebert,
Beverly L. Falcón,
Gary L. Heady,
Bharvin Patel,
V. Peek,
J. Stephens,
J. Stewart,
...
S. Stout,
D. Timm,
S. Um,
Melinda D Willard,
Isabella H. Wulur,
Yi-Fei Zeng,
Yong Wang,
R. Walgren,
S. Betty Yan
|
5 |
2018 |
5
🐜
|
|
🐬
|
Requirements for Catalysis in Mammalian Glycogenin*
T. Hurley,
S. Stout,
E. Miner,
Jing Zhou,
P. Roach
|
4 |
2005 |
4
🐬
|
|
🐜
|
Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.
14 auth.
T. Durham,
V. Klimkowski,
C. J. Rito,
J. Marimuthu,
J. Toth,
Chin Liu,
J. Durbin,
S. Stout,
Lisa A Adams,
C. Swearingen,
...
Chaohua Lin,
M. Chambers,
K. Thirunavukkarasu,
M. Wiley
|
4 |
2014 |
4
🐜
|
|
🐜
|
Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design.
18 auth.
N. E. Hughes,
T. Bleisch,
S. Jones,
Timothy I. Richardson,
R. Doti,
Yong Wang,
S. Stout,
G. L. Durst,
M. Chambers,
J. Oskins,
...
Chaohua Lin,
Lisa A Adams,
T. Page,
R. Barr,
R. Zink,
H. Osborne,
C. Montrose‐Rafizadeh,
B. Norman
|
4 |
2016 |
4
🐜
|
|
🐜
|
Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.
19 auth.
L. L. Winneroski,
M. A. Schiffler,
J. Erickson,
P. May,
S. Monk,
D. Timm,
J. Audia,
J. Beck,
L. Boggs,
Anthony R. Borders,
...
R. Boyer,
R. Brier,
K. J. Hudziak,
V. Klimkowski,
Pablo Garcia Losada,
B. M. Mathes,
S. Stout,
B. Watson,
Dustin J Mergott
|
4 |
2015 |
4
🐜
|
|
🐜
|
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
26 auth.
L. L. Winneroski,
J. Erickson,
S. J. Green,
J. E. Lopez,
S. Stout,
W. Porter,
D. Timm,
J. Audia,
M. Barberis,
J. Beck,
L. Boggs,
Anthony R. Borders,
R. Boyer,
R. Brier,
E. Hembre,
...
J. Hendle,
P. García-Losada,
J. M. Mínguez,
B. M. Mathes,
P. May,
S. Monk,
Z. Rankovic,
Yuan Shi,
B. Watson,
Zhixiang Yang,
Dustin J Mergott
|
3 |
2019 |
3
🐜
|
|
🐜
|
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
26 auth.
D. McKinzie,
L. L. Winneroski,
S. J. Green,
E. Hembre,
J. Erickson,
B. Willis,
S. Monk,
C. Aluise,
T. K. Baker,
J. E. Lopez,
J. Hendle,
J. Beck,
R. Brier,
L. Boggs,
Anthony R. Borders,
...
Patrick J. Cocke,
P. García-Losada,
S. Lowe,
B. M. Mathes,
P. May,
W. Porter,
S. Stout,
D. Timm,
B. Watson,
Zhixiang Yang,
Dustin J Mergott
|
3 |
2021 |
3
🐜
|
